Document is current
Any future updates will be listed below
-
Authors
Wen, Sean
Kuri-Morales, Pablo https://orcid.org/0000-0002-0704-9507
Hu, Fengyuan
Nag, Abhishek
Tachmazidou, Ioanna
Deevi, Sri V. V. https://orcid.org/0000-0002-0405-4335
Taiy, Haeyam
Smith, Katherine R. https://orcid.org/0000-0002-0329-5938
Loesch, Douglas P. https://orcid.org/0000-0001-5716-4557
Burren, Oliver S.
Dhindsa, Ryan S. https://orcid.org/0000-0002-8965-0813
Wasilewski, Sebastian
Alegre-Díaz, Jesus https://orcid.org/0000-0001-9390-3871
Berumen, Jaime https://orcid.org/0000-0001-6707-3317
Emberson, Jonathan https://orcid.org/0000-0001-7792-9422
Torres, Jason M. https://orcid.org/0000-0002-7537-7035
Collins, Rory
Carss, Keren https://orcid.org/0000-0003-4939-156X
Wang, Quanli
Petrovski, Slavé https://orcid.org/0000-0002-1527-961X
Tapia-Conyer, Roberto https://orcid.org/0000-0003-3814-2904
Fabre, Margarete A.
Harper, Andrew R. https://orcid.org/0000-0001-5327-0328
Vassiliou, George S. https://orcid.org/0000-0003-4337-8022
Mitchell, Jonathan https://orcid.org/0000-0003-3792-4058
- License Information
-
More Information
Article History
Received: 7 February 2024
Accepted: 9 January 2025
First Online: 13 February 2025
Competing interests
: S. Wen, F.H., A.N., I.T., S.V.V.D., H.T., K.R.S., K.C., D.P.L., O.S.B., R.S.D., S. Wasilewski, Q.W., S.P., M.A.F., A.R.H., J.M. are current employees and/or stockholders of AstraZeneca. R.C. is the chair of the data monitoring committee of the PROMINENT trial and the deputy chair of a not-for-profit clinical trial company (PROTAS) unrelated to this work. The other authors declare no competing interests.
